Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
31
05
2019
accepted:
06
09
2019
revised:
05
09
2019
pubmed:
20
11
2019
medline:
7
4
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer. Different scoring methods have been used to assess its status, resulting in a wide range of positivity rates. We use the European Thoracic Oncology Platform Lungscape non-small cell lung carcinoma cohort to explore this issue. PD-L1 expression was assessed via immunohistochemistry on tissue microarrays (up to four cores per case), using the DAKO 28-8 immunohistochemistry assay, following a two-round external quality assessment procedure. All samples were analyzed under the same protocol. Cross-validation of scoring between tissue microarray and whole sections was performed in 10% randomly selected samples. Cutoff points considered: ≥1, 50 (primarily), and 25%. At the two external quality assessment rounds, tissue microarray scoring agreement rates between pathologists were: 73% and 81%. There were 2008 cases with valid immunohistochemistry tissue microarray results (50% all cores evaluable). Concordant cases at 1, 25, and 50% were: 85, 91, and 93%. Tissue microarray core results were identical for 70% of cases. Sensitivity of the tissue microarray method for 1, 25, and 50% was: 80, 78, and 79% (specificity: 90, 95, 98%). Complete agreement between tissue microarrays and whole sections was achieved for 60% of the cases. Highest sensitivity rates for 1% and 50% cutoffs were detected for higher number of cores. Underestimation of PD-L1 expression on small samples is more common than overestimation. We demonstrated that classification of PD-L1 on small biopsy samples does not represent the overall expression of PD-L1 in all non-small cell cancer carcinoma cases, although the majority of cases are 'correctly' classified. In future studies, sampling more and larger biopsies, recording the biopsy size and tumor load may permit further refinement, increasing predictive accuracy.
Identifiants
pubmed: 31740722
doi: 10.1038/s41379-019-0383-9
pii: S0893-3952(22)00858-4
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
792-801Investigateurs
Rolf A Stahel
(RA)
Rafael Rosell
(R)
Fiona Blackhall
(F)
Urania Dafni
(U)
Keith M Kerr
(KM)
Miguel Angel Molina
(MA)
Lukas Bubendorf
(L)
Walter Weder
(W)
Erik Thunnissen
(E)
Solange Peters
(S)
Stephen Finn
(S)
Anita Hiltbrunner
(A)
Roswitha Kammler
(R)
Thomas Geiger
(T)
Nesa Marti
(N)
Zoi Tsourti
(Z)
Varvara Polydoropoulou
(V)
Panagiota Zygoura
(P)
Marianne Nicolson
(M)
David A J Stevenson
(DAJ)
William Mathieson
(W)
Egbert Smit
(E)
Teodora Radonic
(T)
Alex Soltermann
(A)
Undine Rulle
(U)
Alessandra Curioni
(A)
Steven G Gray
(SG)
Kathy Gately
(K)
Martin Barr
(M)
Peter Meldgaard
(P)
Line B Madsen
(LB)
Spasenija Savic
(S)
Didier Lardinois
(D)
Kristiaan Nackaerts
(K)
Christophe Dooms
(C)
Els Wauters
(E)
Sara Van Der Borght
(S)
Wojciech Biernat
(W)
Ania Wrona
(A)
Witold Rzyman
(W)
Jacek Jassem
(J)
Hendrik Dienemann
(H)
Thomas Muley
(T)
Arne Warth
(A)
Antonio Marchetti
(A)
Graziano De Luca
(G)
Alessia di Lorito
(A)
Anne-Marie Dingemans
(AM)
Ernst-Jan M Speel
(EM)
Andrea Ruland
(A)
Saraswati Pokharel
(S)
Richard Cheney
(R)
Philip Ferenczy
(P)
Anne Marie Quinn
(AM)
Lynsey Franklin
(L)
Paul Baas
(P)
Kim Monkhorst
(K)
Bart van de Wiel
(B)
Carlos Camps
(C)
Miguel Martorell
(M)
Atilio Navarro
(A)
Références
Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol. 2016;34:1676–88.
doi: 10.1200/JCO.2015.63.8049
Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018;124:248–61.
doi: 10.1002/cncr.31105
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.
doi: 10.1186/s40425-018-0316-z
Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35:3867–76.
doi: 10.1200/JCO.2017.74.7642
Nakamura S, Hayashi K, Imaoka Y, Kitamura Y, Akazawa Y, Tabata K, et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS ONE. 2017;12:e0186192.
doi: 10.1371/journal.pone.0186192
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, et al. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol. 2014;9:1675–84.
doi: 10.1097/JTO.0000000000000320
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, et al. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project. Ann Oncol 2018;29. https://doi.org/10.1093/annonc/mdx629 .
Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32:2780–87.
doi: 10.1200/JCO.2013.54.5921
Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, et al. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer 2019;131:95–103.
doi: 10.1016/j.lungcan.2019.03.012
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017;125:896–907.
doi: 10.1002/cncy.21937
Stoy SP, Rosen L, Mueller J, Murgu S. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. Cancer Cytopathol. 2018;126:122–8.
doi: 10.1002/cncy.21941
Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, et al. EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer. Clin Lung Cancer. 2017;18:527–34:e1.
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
doi: 10.1001/jamaoncol.2015.3638
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147–53.
doi: 10.1093/annonc/mdv489
Bigras G, Mairs S, Swanson PE, Morel D, Lai R, Izevbaye I. Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non–small cell lung carcinomas. Appl Immunohistochem Mol Morphol 2018;10:701–8.
Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Mod Pathol. 2017;30:530–8.
doi: 10.1038/modpathol.2016.213
Skov BG, Skov T. Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol. 2017;25:453–9.
doi: 10.1097/PAI.0000000000000540
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078–92.
doi: 10.1056/NEJMoa1801005
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
doi: 10.1056/NEJMoa1501824
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33.
doi: 10.1200/JCO.2017.74.3062
Gagné A, Enlow W, Pigeon MA, Orain M, Turcotte S, Bossé Y, et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays. Am J Surg Pathol. 2018;42:687–94.
doi: 10.1097/PAS.0000000000001138
Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol 2018;13:1113–20.
Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol. 2017;30:340–9.
doi: 10.1038/modpathol.2016.186
Scorer P, Scott M, Lawson N, Ratcliffe MJ, Barker C, Rebelatto MC, et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagn Pathol. 2018;13:1–10.
doi: 10.1186/s13000-018-0725-9
Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol. 2010;5:448–52.
doi: 10.1097/JTO.0b013e3181ca12c4
Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76:1–18.
doi: 10.1016/j.lungcan.2011.10.017
van Seijen M, Brcic L, Gonzales AN, Sansano I, Bendek M, Brcic I, et al. ETOP Impact of delayed and prolonged fixation on the evaluation ofimmunohistochemical staining on lung carcinoma resection specimen. Virchows Arch 2019;475:191–9.
doi: 10.1007/s00428-019-02595-9